Impact of meningococcal C conjugate vaccination campaign in Emilia-Romagna, Italy
Authors:
- Maria Grazia PascucciMPMaria Grazia Pascucci
- Valentina Di GregoriVGValentina Di Gregori
- Gabriella FrascaGFGabriella Frasca
- Paola RucciPRPaola Rucci
- Alba Carola FinarelliAFAlba Carola Finarelli
- Laura MoschellaLMLaura Moschella
- Bianca Maria BorriniBBBianca Maria Borrini
- Francesca CavriniFCFrancesca Cavrini
- Giovanna LiguoriGLGiovanna Liguori
- Vittorio SambriVittorio Sambri
- Paolo BonanniPBPaolo Bonanni
- Maria Pia FantiniMFMaria Pia Fantini
Open Access
- 30 December 2013
- journal article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 10 (3) , 671-676
Abstract
The incidence of reported meningococcal disease in Italy is among the lowest in Europe. The trend of the disease was increasing up to 2005 and then declined after the gradual introduction of a universal Men C vaccination program in 17/21 Italian regions. Since 2006, in Emilia-Romagna region vaccination against Neisseria meningitidis serogroup C was actively offered free of charge in a single dose to the age groups 12–15 months and 14–15 years, in addition to people with defined epidemiological risk. Our aim was to measure the impact of vaccination on the incidence of meningococcal disease caused by different serogroups among the population of Emilia Romagna Region, Northern Italy (approximately 4.5 million inhabitants) subdivided by age. Using surveillance data, we computed the incidence rates of Neisseria meninigitidis related invasive disease per 100.000 inhabitants for the years 2000 to 2012. In addition, the percentage change in incidence and the mortality rates were calculated. Results indicate a 70.1% decrease in the incidence of meningococcus C-related invasive disease after the introduction of MenC universal vaccination. No case of serogroup C related infection was observed since 2006 in children aged 1–4 years. These findings suggest that the single-dose vaccination strategy against serogroup C N.meningitidis targeted to the age groups 12–15 months and 14–15 years was effective in the Emilia-Romagna population. However, the occurrence of two cases of meningiditis in a 5-month child and in a 9-years child suggests caution and careful consideration in surveillance for the next years.Keywords
This publication has 20 references indexed in Scilit:
- Impact on disease incidence of a routine universal and catch-up vaccination strategy against Neisseria meningitidis C in Tuscany, ItalyVaccine, 2012
- Meningococcal disease serogroup CRisk Management and Healthcare Policy, 2012
- Current immunization policies for pneumococcal, meningococcal C, varicella and rotavirus vaccinations in ItalyHealth Policy, 2011
- Young-adult carriers ofNeisseria meningitidisin Puglia (Italy): Will the pattern of circulating meningococci change following the introduction of meningococcal serogroup C conjugate vaccines?Human Vaccines, 2010
- Immunity against Neisseria meningitidis Serogroup C in the Dutch Population before and after Introduction of the Meningococcal C Conjugate VaccinePLOS ONE, 2010
- Serogroup C Neisseria meningitidis invasive infection: analysis of the possible vaccination strategies for a mass campaignActa Paediatrica, 2010
- Meningococcal carriage and disease—Population biology and evolutionVaccine, 2009
- Changes in the evolution of meningococcal disease, 2001–2008, Catalonia (Spain)Vaccine, 2009
- PROTECTION FROM ROUTINE VACCINATION AT THE AGE OF 14 MONTHS WITH MENINGOCOCCAL SEROGROUP C CONJUGATE VACCINE IN THE NETHERLANDSThe Pediatric Infectious Disease Journal, 2006
- Impact of meningococcal C conjugate vaccine in the UKJournal of Medical Microbiology, 2002